Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.31 |
| ▸ | PGR | P06401 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3087170 | 1.00 | NR1I2 (0.31) | NR1I2PGRESR1PPARGHSD17B10 | |
| SCHEMBL14184951 | 1.00 | NR1I2 (0.31) | NR1I2PGRESR1PPARGHSD17B10 | |
| SCHEMBL3391751 | 0.92 | KDM4E (0.31) | NR1I2HSD17B10TDP1 | |
| SCHEMBL2453654 | 0.92 | KDM4E (0.31) | NR1I2PGRESR1PPARGHSD17B10 | |
| SCHEMBL3076794 | 0.92 | KDM4E (0.31) | NR1I2PGRESR1PPARGHSD17B10 | |
| SCHEMBL14174247 | 0.92 | KDM4E (0.31) | NR1I2HSD17B10TDP1 | |
| SCHEMBL12306375 | 0.88 | — | — | |
| SCHEMBL3073253 | 0.88 | — | — | |
| SCHEMBL14184483 | 0.88 | — | — | |
| SCHEMBL2453074 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445476-B2 | Carbacephem β-lactam antibiotics | ACHAOGEN, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110224186-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| EP-2205600-A1 | CARBACEPHEM ß -LACTAM ANTIBIOTICS | Achaogen, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009055696-A1 | CARBACEPHEM β-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224186-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | MGAM, MGAM2, B2M | NR1I2 249/4885PGR 3582/4885ESR1 763/4885 |
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | MGAM, MGAM2, B2M | NR1I2 466/4885PGR 3387/4885ESR1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.